ReviewCell communication and signaling : CCS2025

Glioma drug development benefits from emerging phase 0 and window-of-opportunity trial paradigm.

Shenzhong Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.